Table I ()Effects of MEL/NB-UVB Alone (A), MEL/NB-UVB +MT (B), and MEL/NB-UVB +MTK (C) on Epidermal Melanocytes/Melanoblasts and Dermal Collagen and Elastin Fibers in the Vitiliginous Skin No Gender (Age) Skin Site MEL/NB-UVB (No. of sess) Dose (j/cm2) MT/MTK (Days) M Non M Les M Tre Mb Non Mb Les Mb Tre Coll Non Coll Les Coll Tre Elas Non Elas Les Elas Tre 28 M (71) Chin MEL(2) 0.8 12 79.6 0 16.9 106.6 0 38.4 ↑↑↑ ↑↑↑ ↑↑↑ ↑↑ ↓↓ ↑↑ 29 M (13) Chin NB(2) 0.6 5 79.2 0 0 104.8 0 0 ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↓↓↓ ↓↓↓ 30 F (23) Hip NB(1) 1.0 6 103.0 0 0 94.8 0 0 ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↓↓↓ ↑↑ 31 F (8) Face MEL(3) 0.7 10 85.0 0 0 97.1 0 0 ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↓↓↓ ↑↑↑ 32 M (17) Chin MEL(4) 0.4 14 78.4 0 0 108.1 0 0 ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↓↓↓ ↑↑↑ 33 M (23) Nose MEL (4) 1.0 6 153.3 0 0 97.5 0 0 ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↓↓ ↓↓ 34 F (20) Areola MEL(7) +NB(3) 1.7 31 72.1 0 0 80.2 0 0 ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↓↓ ↓↓ (C) MEL/NB-UVB +MTK 35 F (76) Face NB(6) 3.0 14 150.5 0 0 107.3 0 0 ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↓↓↓ ↑↑↑ 36 F (28) Chin MEL(4) 0.7 14 70.8 0 0 94.2 0 0 ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↓↓ ↑↑↑ 37 M (36) Neck MEL(3) 0.2 18 77.5 0 0 98.5 0 0 ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↓↓↓ ↑↑↑ 38 F (45) Face MEL(4) +NB(1) 0.8 8 87.5 0 0 90.0 0 0 ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↓↓↓ ↑↑↑ 39 M (10) Head MEL(5) 1.0 23 157.4 0 0 123.8 0 0 ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↓↓↓ ↑↑↑ 40 F (21) Head MEL(3) 0.4 17 86.3 0 0 113.2 0 0 ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↓↓↓ ↑↑↑ 41 F (11) Shoulder MEL(7) +NB(7) 3.6 104 127.5 0 16.3 103.8 0 17.8 ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↓↓↓ ↑↑↑ 42 M (4) Head MEL(27) 9.5 75 98.3 0 58.4 95.8 0 61.9 ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↓↓ ↑↑↑ 43 M (33) Neck NB(7) 4.6 25 134.8 0 29.5 117.4 0 19.0 ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↓↓ ↑↑↑ 44 M (15) Head MEL(1) +NB(21) 17.9 168 110.9 0 105.7 104.3 0 98.9 ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↓↓ ↑↑↑ 45 M (65) Face MEL(7) +NB(6) 5.1 24 120.8 0 0 106.5 0 0 ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↓↓↓ ↑↑↑ 46 F (72) Neck MEL (2) +NB(1) 2.5 13 144.7 0 41.3 128.4 0 35.7 ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↓↓↓ ↑↑↑ 47 F (27) Face NB(6) 3.5 21 124.9 0 8.7 101.5 0 45.2 ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↓↓↓ ↑↑↑ 48 M (21) Chin MEL(3) +NB(2) 1.2 14 84.9 0 51.1 114.2 0 67.5 ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↓↓ ↑↑↑ 49 M (37) Neck MEL (3) 0.3 21 105.3 0 18.8 114.2 0 20.4 ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↓↓↓ ↑↑↑ 50 F (56) Hand MEL(25) +NB(1) 204.9 44 87.0 0 3.7 119.7 0 3.7 ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↓↓↓ ↑↑↑ 51 F (71) Arm NB(20) 21.0 76 98.5 0 107.6 103.5 0 97.5 ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↓↓ ↑↑↑ Sessions (sess) of MEL (308 nm) and/or NB-UVB (NB, 311 nm) were performed on the skin of 51 vitiligo patients. MT, MEL/NB-UVB +FFC +collagen peptide +elastin peptide MTK, MT +UCB-MSCCS F, female M, male M, melanocyte population/0.1 mm2 Mb, melanoblast population/0.1 mm2 Non, nonlesional Les, lesional Tre, treatment with MEL/NB-UVB and/or MT/MTK Coll, collagen fiber Elas, elastin fiber ↓slightly decreased ↓↓decreased ,↓↓↓decreased ,dramatically ↑slight recovery ↑↑moderate ,recovery or slightly reduced density compared with nonlesional skin ↑↑↑full ,recovery. 394 JOURNAL OF COSMETIC SCIENCE

395 MESENCHYMAL STEM CELL-DERIVED FACTORS 1.5 mm in depth) were taken from each skin area using an electric micro drill (SIRIUS NT Micro at 90 g Gerlach SIRIUS NT Micro, Eduard Gerlach GmbH, Lübbecke, Germany) as reported previously (10). Three punch biopsies of nonlesional (area one) and lesional (area two) skin were fixed at the time of initiation, and those of the treated skin (areas three, four, and five) were fixed at the time of cessation. HISTOCHEMISTRY Skin samples were fixed with 16% neutral formalin in phosphate buffer (pH 7.0) for 16–24 hours at 2°C. The samples were then washed with distilled water and incubated with a 0.1% L-3,4-dihydroxyphenylalanine solution in phosphate buffer (pH 7.4) for 16–24 hours at 37°C (1). The DOPA reaction reveals only tyrosinase-containing differentiated melanocytes. Serial sections 10 µm thick were deparaffinized and counterstained with eosin. For the combined DOPA–premelanin reaction (combined DOPA–ammoniacal silver nitrate staining), deparaffinized sections after the DOPA reaction were incubated in a 10% ammoniacal silver nitrate solution for 5 minutes at 58°C (1,10). Ammoniacal silver nitrate staining after the DOPA reaction was used for the light microscopic detection of melanoblasts with unmelanized stage I and II melanosomes in addition to differentiated melanocytes, since metallic silver particles were deposited on stages I, II, III, and IV melanosomes with a high degree of selectivity (1). The specimens were also counterstained with eosin. The number of melanocytes (cells positive to the DOPA reaction) and the number of melanoblasts plus melanocytes (cells positive to the combined DOPA–premelanin reaction) in the epidermis were counted through 10 consecutive sections (each individual datum was an average of 3 skin samples) and expressed per 0.1 mm2 of the interfollicular epidermis. The number of melanoblasts was calculated by subtracting the number of melanocytes from the combined number of melanoblasts and melanocytes. A “melanoblast” is defined here as an unpigmented cell that possesses no tyrosinase activity. For Azan staining (collagen staining), deparaffinized sections were first treated with Mallory’s azocarmine G for 7 minutes at room temperature. Then the specimens were treated with 5% phosphotungstic acid for 30 minutes at room temperature for the differentiation of azocarmine G. Next, they were stained with Mallory’s aniline blue orange G for 3 minutes at room temperature. They were dehydrated with a graded series of alcohols and made transparent by xylene and finally embedded with Canada balsam. For elastin staining, deparaffinized sections were first treated with HBs antigen oxidizing solution for 10 minutes at room temperature. Then the specimens were treated with 2% oxalic acid solution for 30 seconds. After treating the specimens with 95% ethanol for 2 minutes, they were treated with Victoria blue for 18–24 hours at room temperature. After treating with 70% ethanol to differentiate Victoria blue for 25 minutes, they were treated with nuclear fast red for 20 minutes at room temperature. They were dehydrated with graded series of alcohols and made transparent by xylene and finally embedded with Canada balsam (5). STATISTICS The statistical significance of the differences in the number of melanocytes and melanoblasts, in the number of sessions of MEL/NB-UVB, and in the total doses of MEL/NB-UVB